iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2008
Recruiting
1
100.0%
No approval data available
- iBio is developing a selective bispecific antibody targeting activin A, myostatin (GDF8), and GDF11 to treat pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). - The company expects to declare an optimized development candidate in the third quarter of 2026, validated for potency, selectivity, manufacturability, and in vivo efficacy. - iBio's approach aims to address multiple core drivers of PH-HFpEF biology simultaneously while avoiding safety issues linked to broader TGF-β ligand blockade. - The program builds on iBio's obesity-focused pipeline and leverages shared biological pathways between functional decline in obesity and PH-HFpEF mechanisms.
- iBio's IBIO-610, a first-in-class Activin E antibody, reduced visceral fat by 6.7% and total fat mass by 5.2% in obese non-human primates despite high-calorie diet. - The treatment demonstrated fat-selective weight loss while maintaining lean mass, with an extended 33.2-day half-life supporting potential twice-yearly dosing. - Results align with previous rodent studies and human clinical trials targeting the Activin E pathway, supporting continued development for obesity and cardiometabolic diseases. - The complete dataset including additional biomarkers will be presented at scientific conferences throughout 2026.
- iBio announces new non-human primate data for IBIO-610, a potentially first-in-class Activin E antibody, showing a 33.2-day half-life in obese primates and predicting up to 100 days in humans. - The extended half-life could enable twice-yearly dosing for obesity treatment, potentially improving patient experience compared to current frequent injection regimens. - Previous mouse model data demonstrated that IBIO-610 drives fat-selective weight loss, synergizes with GLP-1 therapies, and prevents weight regain after GLP-1 discontinuation. - The findings will be presented at ObesityWeek 2025, highlighting IBIO-610's potential as a next-generation therapy addressing biology beyond appetite control.
- iBio will present new preclinical data on its Activin E antibody IBIO-610 at ObesityWeek 2025 and PEGS Europe 2025, showcasing results from non-human primate studies. - The company's research suggests that inhibiting Activin E signaling could deliver fat-selective weight loss and support long-term weight maintenance while enhancing GLP-1 therapy benefits. - IBIO-610 represents a first-in-class approach that may overcome key limitations of current obesity therapies and advance next-generation cardiometabolic treatments.
- iBio will present promising preclinical data on its long-acting Myostatin antibody IBIO-600 and Activin E targeting therapies for obesity and cardiometabolic diseases. - The company will announce a third target in its AstralBio Collaboration during a June 24 conference call, expanding its precision antibody therapy pipeline. - iBio's AI-driven approach combines proprietary 3D modeling with computational biology to develop next-generation antibody medicines with potentially better tolerability and sustainable efficacy. - The biotech company is positioning itself to address significant unmet medical needs in obesity treatment through targeted, longer-lasting therapeutic approaches.
- University of Illinois Chicago researchers have developed a novel antibiotic that could make it 100 million times harder for bacteria to develop resistance, potentially revolutionizing treatment of drug-resistant infections. - Illinois faces a growing superbug crisis, accounting for 15% of all U.S. cases of C. auris, with cases skyrocketing from 11 in 2017 to 276 in 2022, highlighting the urgent need for new antimicrobial treatments. - The proposed PASTEUR Act aims to address the economic challenges of antibiotic development by creating a subscription model where the government contracts with developers, potentially revitalizing the struggling antimicrobial sector.
- iBio has secured a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, discovered using iBio's patented Machine-Learning Antibody Engine. - Preclinical studies demonstrated the antibody's ability to induce fat-selective weight loss while preserving muscle mass, with synergistic effects when combined with GLP-1 receptor agonists. - The novel therapeutic approach could potentially reverse obesity, prevent diabetes, and improve cardiometabolic health by inhibiting Activin E-mediated signaling that regulates energy balance and fat distribution.
• Pharmaceutical companies warn in SEC filings that Trump administration's FDA staffing and budget cuts could significantly delay or halt new drug approvals and commercialization processes. • Recent layoffs of hundreds of FDA employees have sparked industry-wide concerns about disruptions to clinical trials, grant applications, and regulatory oversight activities. • Multiple biotech firms, including Xenon Pharmaceuticals and Rezolute, report that reduced FDA capacity could negatively impact their drug development timelines and business operations.
